EVALUASI PENGGUNAAN ANTIBIOTIK PADA PASIEN INFEKSI SALURAN NAFAS BAWAH (PNEUMONIADAN BRONKITIS AKUT) DI BALAI BESAR KESEHATAN PARU MASYARAKAT SURAKARTA

• المؤلفون الرئيسيون: , ARI SUKMAWATI MAKNA, , Prof. Dr. Agung Endro Nugroho, M.Si.,Apt
• التنسيق: Theses and Dissertations NonPeerReviewed
• منشور في: [Yogyakarta] : Universitas Gadjah Mada 2014
• الموضوعات: ETD
• الوصول للمادة أونلاين: https://repository.ugm.ac.id/133036/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=73584

Respiratory tract infections are a major cause of morbidity and mortality in the world. Drug use antibiotic in hospitals are usually still based on experience (empirical). Improper use of antibiotics can cause a variety of problems. The research aims is to describe the use antibiotic and suitable use antibiotic with the guidelines of the outcome of therapy in patients with lower respiratory tract infections (pneumonia and acute bronchitis) at Balai Besar Kesehatan Paru Masyarakat Surakarta. Research conducted with observational study devise and use crosssectional design, Intake of patient lower respiratory tract infections (pneumonia and acute bronchitis) data done by prospectively performed in outpatient installation Balai Besar Kesehatan Paru Masyarakat Surakarta from January to February 2014. Evaluated data the suitability of use of the guideline antibiotic with the outcome therapy after 5 days. Data were analyzed descriptively and presented in tabular form in the form of percentages and chi square. During research in BBKPM found 113 patients diagnosed to lower respiratory tract infections (pneumonia and acute bronchitis) inclusion criteria from January to February 2014, The use of antibiotics in patients with lower respiratory tract infections are first-generation cephalosporins (Cefadroxil 32%), third-generation cephalosporins (cefixime 28%), followed by the class of macrolides (azithromycin 26%, Spiramycin 4%, 3% Clarithromycin, Erythromycin 1%), Flourokuinolon group (4% Ciprofloxacin, Levofloxacin 2%) and a class of beta-lactam (amoxicillin clavulanate 1%) . Suitability guidelines do not affect the use of antibiotic with outcomes therapy (clinical response of patients cured and not cured) in patients lower respiratory tract infections in BBKPM Surakarta (p> 0.05).